Estrogenic activity and cytotoxicity of six anticancer drugs detected in water systems

Science of the Total Environment

Volumn 485-486, Issue 1, 2014, Pages 216-222

  Parrella, Alfredo ^a   Lavorgna, Margherita ^a   Criscuolo, Emma ^a   Russo, Chiara ^a   Isidori, Marina ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Anticancer drugs; Cytostatics; Cytotoxicity; Endocrine activity; Environmental pollution

Indexed keywords

CELL PROLIFERATION; DRUG PRODUCTS; EFFLUENTS; PLATINUM COMPOUNDS; YEAST;

5-FLUOROURACIL; ANTICANCER DRUG; CYTOSTATICS; CYTOTOXIC ACTIVITIES; ENDOCRINE ACTIVITY; ENVIRONMENTAL POLLUTIONS; ESTROGENIC ACTIVITIES; WASTE WATER SYSTEMS;

CYTOTOXICITY;

CAPECITABINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMATINIB;

CONCENTRATION (COMPOSITION); ENDOCRINE DISRUPTOR; ESTROGENIC COMPOUND; POLLUTANT REMOVAL; TOXICITY; WATER TREATMENT;

ARTICLE; CELL STRAIN MCF 7; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; WATER SUPPLY;

ANTICANCER DRUGS; CYTOSTATICS; CYTOTOXICITY; ENDOCRINE ACTIVITY; ENVIRONMENTAL POLLUTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; ENDOCRINE DISRUPTORS; ENVIRONMENTAL MONITORING; MCF-7 CELLS; WATER POLLUTANTS, CHEMICAL;

EID: 84898402304     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2014.03.050     Document Type: Article

References (51)

1. Berridge M.V., Tan A.S. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993, 303:474-482.
2. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ Int 2012, 39:73-86.
3. Bielawski K., Bielawska A., Poplawska B., Surazynski A., Czarnomysy R. The effect of a novel dinuclear platinum complex with berenil and 2-picoline ligands on growth of human breast cancer cells. Acta Pol Pharm 2010, 67:609-614.
4. Castiglia L., Miraglia N., Pieri M., Simonelli A., Basilicata P., Genovese G., et al. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department. J Occup Health 2008, 50:48-56.
5. Catastini C., Mullot J.-U., Boukari S., Mazellier P., Levi Y., Cervantes P., et al. Assessment of antineoplastic drugs in effluents of two hospitals|. Eur J Wat Qual 2008, 39:171-180.
6. Ciarcia R., Vitiello M.T., Galdiero M., Pacilio C., Iovane V., D'Angelo D., et al. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol 2012, 227:2798-2803.
7. Clubbs R.L., Brooks Daphnia magna responses to a vertebrate estrogen receptor agonist and antagonist: a multigenerational study. Ecotoxicol Environ Saf 2007, 67:385-398.
8. Constantine L.A., Huggett D.B. A comparison of the chronic effects of human pharmaceuticals on two cladocerans, Daphnia magna and Ceriodaphnia dubia. Chemosphere 2010, 80:1069-1074.
9. De Angelis C., Milano M., Stanzione B., Gargiulo P., De Placido S., Arpino G. Combination of cytotoxic drugs for patients with HER2-negative metastatic breast cancer. Comb Prod Ther 2013, 3:25-37.
10. DescÔteaux C., Leblanc V., Bélanger G., Parent S., Asselin E., Bérubé G. Improved synthesis of unique estradiol-linked platinum (II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta. Steroids 2008, 73:1077-1089.
11. Fawwaz S.A., Iskandar Z.A., Abdul-Rani S. The effects of chemotherapeutic drugs on viability, apoptosis, and surviving expression in MCF-7 cells. Acta Histochem Cytochem 2005, 38:323-330.
12. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76:122-159.
13. Fent K., Escher C., Caminada D. Estrogenic activity of pharmaceuticals and pharmaceutical mixtures in a yeast reporter gene system. Reprod Toxicol 2006, 22:175-185.
14. Garabedian M.J., Iniguez-Lluhi J.A., Kralli A. Yeast as a system for the study of nuclear receptor function. Nuclear receptors 1999, 233-259. Oxford University Press, New York. D. Picard (Ed.).
15. Guzeloglu-Kayisli O., Halis G., Taskiran S., Kayisli U.A., Arici A. DNA-binding ability of NF-κB is affected differently by ERα and ERβ and its activation results in inhibition of estrogen responsiveness. Reprod Sci 2008, 15:493-505.
16. Isidori M., Bellotta M., Cangiano M., Parrella A. Estrogenic activity of pharmaceuticals in the aquatic environment. Environ Int 2009, 35:826-829.
17. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human environment. Trends Anal Chem 2008, 30:1065-1087.
18. Khvatova G.I., Semeikin A.V. Molecular-biological problems of drugs and mechanism of drug action. Comparative cytotoxicity of capecitabine and xeloda on cultured MCF-7, HT-12, and rat thymocytes. Pharm Chem J 2011, 44:651-653.
19. Kosjek T., Heath E. Occurrence, fate and determination of cytostatic pharmaceuticals in the environment. Trends Anal Chem 2011, 30:1065-1087.
20. Kosjek T., Perko S., Žigon D., Heath E. Fluorouracil in the environment: analysis, occurrence, degradation and transformation. J Chromatogr A 2013, 1290:62-72.
21. Kovalova L., McArdell C.S., Hollender J. Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. J Chromatogr 2009, A 1216:1100-1108.
22. Lenz K., Koellensperger G., Hann S., Weissenbacher N., Mahnik S.N., Fuerhacker M. Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 2007, 69:1765-1774.
23. Lukyanova N.Y., Rusetskya N.V., Tregubova N.A., Chekhun V.F. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009, 31:87-91.
24. Mahnik S.N., Rizovski, Furhacker M., Mader R.M. Determination of 5-fluorouracil in hospital effluents. Anal Bioanal Chem 2004, 380:31-35.
25. Mahnik S.N., Rizovski B., Fuerhacker M., Mader R.M. Development of an analytical method for the determination of anthracyclines in hospital effluents. Chemosphere 2006, 65:1419-1425.
26. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66:30-37.
27. Manu K.A., Shanmugam M.K., Ramachandran L., Li F., Fong C.W., Kumar A.P., et al. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clin Cancer Res 2012, 10.1158/1078-0432.
28. Margiotta-Casaluci L., Hannah R.E., Sumpter J.P. Mode of action of human pharmaceuticals in fish: the effects of the 5-alpha-reductase inhibitor, dutasteride, on reproduction as a case study. Aquat Toxicol 2013, 128-129:113-123.
29. Martin J., Camacho-Munoz D., Santos J.L., Aparicio I., Alonso E. Simultaneous determination of a selected group of cytostatic drugs in water using high-performance liquid chromatography-triple-quadrupole mass spectrometry. J Sep Sci 2011, 34:3166-3177.
30. Negreira N., López de Alda M., Barceló D. On-line solid phase extraction-liquid chromatography-tandem mass spectrometry for the determination of 17 cytostatics and metabolites in waste, surface and ground water samples. J Chromatogr A 2013, 1280:64-74.
31. Nuttall M.E., Pendrak I., Emery J.G., Nadeau D.P., Fisher P.W., Nicholson T.A., et al. Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Cancer Chemother Pharmacol 2001, 47(5):437-443.
32. Park J.Y., Lee B.C., Ra J.S., Lee J., Kim S.D. Effect of copper complexation on the estrogenic activities of endocrine-disrupting compounds using E-screen bioassay. Environ Toxicol Chem 2008, 27:535-541.
33. Parrella A., Lavorgna M., Criscuolo E., Russo C., Fiumano V., Isidori M. Acute and chronic toxicity of six anticancer drugs on rotifers and crustaceans. Chemosphere 2014, 10.1016/j.chemosphere.2014.01.013.
34. Pieri M., Castiglia L., Basilicata P., Sannolo N., Acampora A., Miraglia N. Biological monitoring of nurses exposed to doxorubicin and epirubicin by a validated liquid chromatography/fluorescence detection method. Ann Occup Hyg 2010, 54:368-376.
35. Pratilas C.A., Solit D.B. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010, 16:3329-3334.
36. Quiles J.L., Huertas J.R., Battino M., Mataix J., Ramirez-Tortosa M.C. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002, 180:79-95.
37. Robertson J.F.R. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem 2001, 79:209-212.
38. Routledge E.J., Sumpter J.P. Estrogenic activity of surfactants and some of their degradation products assessed using a recombinant yeast screen. Environ Toxicol Chem 1996, 15(3):241-248.
39. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009, 28(12):2733-2743.
40. Saha P., Fortin S., Leblanc V., Parent S., Asselin É., Bérubé G. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer. Steroids 2012, 77:1113-1122.
41. Shanle E.K., Xu W. Endocrine disrupting chemicals targeting estrogen receptor signalling: identification and mechanism of action. Chem Res Toxicol 2011, 24:6-19.
42. Soto A.M., Sonnenschein C., Chung K.L., Fernandez M.F., Olea N., Serrano F.O. The E-screen assay as a tool to identify estrogens; an update on estrogenic environmental pollutants. Environ Health Perspect 1995, 103:113-122.
43. Straub J.O. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe. Integr Environ Assess Manag 2009, 6:540-566.
44. Sumpter J.P. Endocrine disrupters in the aquatic environment: an overview. Acta Hydrochim Hydrobiol 2005, 33:9-16.
45. Vanparys C., Depiereux S., Nadzialek S., Robbens J., Blust R., Kestemont P., et al. Performance of the flow cytometric E-screen assay in screening estrogenicity of pure compounds and environmental samples. Sci Total Environ 2010, 408:4451-4460.
46. Yin J., Shao B., Li K. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull Environ Contam Toxicol 2010, 84:39-45.
47. Zhang T., Zhang Q., Chen D., Jiang J., Zhou Q. Growth inhibition of human breast cancer cell line MDAMB-231 by rosiglitazone through activation of PPARγ. Chin J Clin Oncol 2008, 5:407-412.
48. Zhang J., Chang V.W.C., Giannis A., Wang J.Y. Removal of cytostatic drugs from aquatic environment: a review. Sci Total Environ 2013, 445-446:281-298.
49. Zhao M.R., Zhang Y., Liu W.P., Xu C., Wang L.M., Gan J.Y. Estrogenic activity of lambda-cyhalothrin in the MCF-7 human breast carcinoma cell line. Environ Toxicol Chem 2008, 27:1194-1200.
50. Zounková R., Odráška P., Doležalová L., Hilscherová K., Maršálek B., Bláha L. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 2007, 26:2208-2214.
51. Zounková R., Kovalova L., Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81:253-260.